Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation

开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会

基本信息

  • 批准号:
    10605254
  • 负责人:
  • 金额:
    $ 50.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract In the US, nearly 95,000 patients are waitlisted for a kidney transplant, yet in 2018, only 14,700 received a deceased donor kidney transplant, while nearly 8,500 died or became too sick. The organ shortage is equally intense for liver transplant; in 2018, among more than 14,000 waitlisted patients, only 7,700 received a deceased donor liver transplant while 2,500 died or became too sick. Unfortunately, more than 5,000 kidneys and 2,000 livers from deceased donors were offered for transplant in 2018, but never transplanted. Although a subset of these organs was unsuitable for transplant, data clearly demonstrate that the inability to accurately assess graft quality directly led to many discards and/or undermined our ability to guide organs to appropriate patients. Prior to their organs being offered for transplant, deceased donors are hospitalized for days, often with numerous longitudinal data points (e.g., laboratory values) available to assess organ function. Yet, existing models of graft quality have these major flaws: 1) a reliance on cross-sectional clinical and laboratory data directly prior to procurement; 2) neglect of biologically-relevant, longitudinal data from the donor terminal hospitalization such serial hemodynamics (kidney and liver) and urine output (kidney); and 3) failure to integrate interactions between donor and recipient characteristics. As a result, existing kidney and liver donor risk models have inadequate prediction accuracy (C-statistics of only 0.6-0.65). Our group proposes to advance the field by developing state-of-the art models that make use of extensive, longitudinal donor data during the donor's terminal hospitalization—laboratory biomarkers of organ injury, and measures of organ function and perfusion. Second, we will develop highly robust allograft risk models using the joint modeling approach, which can account for longitudinal donor exposure data and time-to-event outcomes such as graft failure, instead of standard techniques (e.g., Cox regression). Third, we will highlight the real-world impact of the results in terms of population health. We have these specific aims: 1) Develop kidney graft failure models using joint modeling to predict graft failure with higher discrimination and calibration relative to the current kidney donor risk index; 2) Develop liver graft failure risk models using joint modeling to predict graft failure with high discrimination and calibration; 3a) Simulate the change in allograft life years from better pairing organs to recipients based on alignment of projected organ and patient survival; and 3b) Simulate the change in the number of transplants and allograft life years for the transplant population by implementing improved organ quality metrics in organ allocation to decrease discards. The models will be constructed using comprehensive US transplant data and externally validated with data from two Canadian provinces. The grant will also include important exploratory analyses of transplant complications by linking to data from Medicare. We will finally develop a web-based tool to enable real-time predictions of organ outcomes to put the results in the hands of clinicians and other investigators.
项目概要/摘要 在美国,近 95,000 名患者被列入肾移植的候补名单,但 2018 年,只有 14,700 名患者接受了肾移植手术。 死者捐献者肾移植,而近 8,500 人死亡或病重。器官短缺同样严重 强烈进行肝移植; 2018年,在超过14,000名候补患者中,只有7,700人获得了治疗 已故的捐献者进行了肝脏移植,同时有 2,500 人死亡或病重。不幸的是,超过5000个肾脏 2018 年,有 2000 个已故捐献者的肝脏被提供用于移植,但从未进行过移植。虽然一个 这些器官的子集不适合移植,数据清楚地表明无法准确地 评估移植质量直接导致许多丢弃和/或削弱了我们引导器官适当移植的能力 患者。在捐献器官进行移植之前,已故捐献者通常会住院数天 具有大量纵向数据点(例如实验室值)可用于评估器官功能。然而, 现有的移植物质量模型存在以下主要缺陷:1)依赖于横断面临床和实验室 采购前的数据; 2) 忽略来自供体终端的生物学相关的纵向数据 住院治疗,例如连续血流动力学(肾脏和肝脏)和尿量(肾脏); 3) 未能 整合捐赠者和接受者特征之间的相互作用。因此,现有的肾脏和肝脏捐赠者 风险模型的预测精度不足(C 统计量仅为 0.6-0.65)。我们小组建议 通过开发利用广泛的纵向捐赠者数据的最先进的模型来推进该领域的发展 捐献者临终住院期间——器官损伤的实验室生物标志物以及器官的测量 功能和灌注。其次,我们将使用联合建模开发高度稳健的同种异体移植风险模型 方法,可以解释纵向供体暴露数据和事件发生时间结果,例如移植物 失败,而不是标准技术(例如 Cox 回归)。第三,我们将强调现实世界的影响 人口健康方面的结果。我们有以下具体目标:1) 开发肾移植衰竭模型 使用联合建模来预测移植失败,相对于当前模型具有更高的辨别力和校准能力 肾捐献者风险指数; 2) 使用联合建模开发肝移植失败风险模型来预测移植失败 具有较高的辨别力和校准度; 3a) 模拟更好配对导致的同种异体移植物寿命年的变化 根据预计器官和患者生存的一致性向接受者提供器官; 3b) 模拟变化 通过实施改进的移植手术数量和移植人群的同种异体移植生命年 器官分配中的器官质量指标,以减少丢弃。模型将使用构建 全面的美国移植数据,并使用加拿大两个省的数据进行外部验证。补助金 还将包括通过链接到医疗保险数据对移植并发症进行重要的探索性分析。 我们最终将开发一个基于网络的工具来实时预测器官结果,并将结果放入 临床医生和其他研究人员的手中。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
联合器官共享数据库网络中急性智力肝衰竭的分类不一致。
  • DOI:
    10.1016/j.jhep.2021.12.040
  • 发表时间:
    2022-05
  • 期刊:
  • 影响因子:
    25.7
  • 作者:
    Lee, Brian P.;Cullaro, Giuseppe;Vosooghi, Aidan;Yao, Frederick;Panchal, Sarjukumar;Goldberg, David S.;Terrault, Norah A.;Mahmud, Nadim
  • 通讯作者:
    Mahmud, Nadim
Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
  • DOI:
    10.1016/j.jhep.2021.12.034
  • 发表时间:
    2022-05
  • 期刊:
  • 影响因子:
    25.7
  • 作者:
    Mahmud, Nadim;Chapin, Sara;Goldberg, David S.;Reddy, K. Rajender;Taddei, Tamar H.;Kaplan, David E.
  • 通讯作者:
    Kaplan, David E.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Seth Goldberg其他文献

Multivisceral transplantation utilizing hepatitis C virus–viremic donors for hepatitis C virus–negative recipients
利用丙型肝炎病毒阳性供体为丙型肝炎病毒阴性受者进行多器官联合移植
  • DOI:
    10.1016/j.ajt.2024.09.006
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    8.200
  • 作者:
    Vanessa Addison;David Seth Goldberg;Rodrigo Vianna;Eric Martin;Jenn Garcia
  • 通讯作者:
    Jenn Garcia

David Seth Goldberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Seth Goldberg', 18)}}的其他基金

3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
3/4-综合研究:评估综合护理以改善酒精相关性肝病早期肝移植的生物心理社会结果
  • 批准号:
    10710924
  • 财政年份:
    2023
  • 资助金额:
    $ 50.64万
  • 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
  • 批准号:
    10605313
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
  • 批准号:
    10491885
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
  • 批准号:
    10700141
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
  • 批准号:
    10310739
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
  • 批准号:
    10095988
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
  • 批准号:
    10392517
  • 财政年份:
    2021
  • 资助金额:
    $ 50.64万
  • 项目类别:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会
  • 批准号:
    10201592
  • 财政年份:
    2020
  • 资助金额:
    $ 50.64万
  • 项目类别:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会
  • 批准号:
    10413907
  • 财政年份:
    2020
  • 资助金额:
    $ 50.64万
  • 项目类别:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
利用伦理学、流行病学和高质量数据来优化移植肝脏的分配
  • 批准号:
    10356830
  • 财政年份:
    2019
  • 资助金额:
    $ 50.64万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 50.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 50.64万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 50.64万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 50.64万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 50.64万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 50.64万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 50.64万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 50.64万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 50.64万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 50.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了